HRP930751B1 - Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists - Google Patents

Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists

Info

Publication number
HRP930751B1
HRP930751B1 HR930751A HRP930751A HRP930751B1 HR P930751 B1 HRP930751 B1 HR P930751B1 HR 930751 A HR930751 A HR 930751A HR P930751 A HRP930751 A HR P930751A HR P930751 B1 HRP930751 B1 HR P930751B1
Authority
HR
Croatia
Prior art keywords
leukotriene antagonists
unsaturated
acids
compounds
useful
Prior art date
Application number
HR930751A
Other languages
English (en)
Inventor
Michel L Belley
Serge Leger
Patrick Roy
Yi Bin Xiang
Marc Labelle
Daniel Guay
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27082671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP930751(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of HRP930751A2 publication Critical patent/HRP930751A2/hr
Publication of HRP930751B1 publication Critical patent/HRP930751B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR930751A 1990-10-12 1993-04-02 Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists HRP930751B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59688790A 1990-10-12 1990-10-12
US74188891A 1991-08-08 1991-08-08
YU164791A YU48742B (sh) 1990-10-12 1991-10-11 Nezasićene hidroksialkilhinolin kiseline

Publications (2)

Publication Number Publication Date
HRP930751A2 HRP930751A2 (en) 1995-06-30
HRP930751B1 true HRP930751B1 (en) 2000-06-30

Family

ID=27082671

Family Applications (1)

Application Number Title Priority Date Filing Date
HR930751A HRP930751B1 (en) 1990-10-12 1993-04-02 Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists

Country Status (27)

Country Link
EP (1) EP0480717B1 (fr)
JP (1) JP2501385B2 (fr)
KR (1) KR100227716B1 (fr)
CN (1) CN1046711C (fr)
AT (1) ATE165088T1 (fr)
CA (1) CA2053209C (fr)
CY (1) CY2094B1 (fr)
CZ (1) CZ281274B6 (fr)
DE (2) DE69129257T2 (fr)
DK (1) DK0480717T3 (fr)
ES (1) ES2114882T3 (fr)
FI (2) FI104897B (fr)
HK (1) HK1027473A1 (fr)
HR (1) HRP930751B1 (fr)
HU (2) HU222344B1 (fr)
IE (1) IE913609A1 (fr)
IL (3) IL117147A (fr)
LU (1) LU90284I2 (fr)
LV (1) LV12187B (fr)
MX (1) MX9101551A (fr)
NL (1) NL990009I2 (fr)
NO (1) NO914004D0 (fr)
NZ (1) NZ240194A (fr)
PT (1) PT99213B (fr)
SI (1) SI9111647B (fr)
SK (1) SK279944B6 (fr)
YU (1) YU48742B (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
CA2111372C (fr) * 1992-12-22 2007-01-16 Robert N. Young Acides heterocycliques diaryliques condenses en 5,6, antagonistes de la leucotriene
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5438141A (en) * 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
ES2080656B1 (es) * 1993-07-19 1996-10-16 Merck Frosst Canada Inc Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno.
CA2130723C (fr) * 1993-09-03 2006-01-31 Wilhelm Quittmann Methode pour l'obtention de derives de l'acide y-mercaptocarboxylique
DE4339724C1 (de) * 1993-11-22 1995-01-19 Siemens Ag Gasarmatur
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
CA2145735A1 (fr) * 1994-04-21 1995-10-22 Paul Hanselmann Methode de preparation de 5-oxaspiro[2.4]heptan-6-one et nouveaux produits intermediaires intervenant dans le processus
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5750539A (en) * 1995-06-07 1998-05-12 Merck Frosst Canada Heteroaryl diol acids as leukotriene antagonists
US5714488A (en) * 1995-10-03 1998-02-03 Abbott Laboratories Bis-heteroarylylmethoxyphenyl ketone derivatives as inhibitors of leukotriene biosynthesis
US5668150A (en) * 1996-07-26 1997-09-16 Abbott Laboratories Non-symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
FR2751969B1 (fr) 1996-08-01 1998-12-04 Centre Nat Rech Scient Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6221880B1 (en) 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
JP4308667B2 (ja) * 2002-02-06 2009-08-05 デルマー ケミカルズ インコーポレーテッド １−（メルカプトメチル）−シクロプロパン酢酸の調製方法
CA2371048C (fr) 2002-02-06 2011-01-04 Delmar Chemicals Inc. Procede de preparation d'acide 1-(mercaptomethyl)cyclopropylacetique
AU2003209043A1 (en) * 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
WO2004108679A1 (fr) 2003-06-06 2004-12-16 Morepen Laboratories Limited Procede de preparation ameliore d'acide montelukast et de sel de sodium de celui-ci sous forme amorphe
ATE522507T1 (de) 2003-10-10 2011-09-15 Synhton B V Montelukast in fester phase
US20070225325A1 (en) * 2004-01-28 2007-09-27 Pliva-Istrazivanje I Razvoj D.O.O. Solid Forms of Montelukast Acid
EP1760077A1 (fr) * 2004-01-30 2007-03-07 Teva Pharmaceutical Industries Ltd. Formes polymorphes du l'acide libre montelukast
US20050187243A1 (en) * 2004-01-30 2005-08-25 Valerie Niddam-Hildesheim Montelukast free acid polymorphs
NZ548873A (en) 2004-02-03 2010-04-30 Chemagis Ltd Stable amorphous forms of montelukast sodium
KR100815670B1 (ko) * 2004-04-21 2008-03-20 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트 나트륨을 제조하는 방법
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7858793B2 (en) 2004-07-19 2010-12-28 Chava Satyanarayana Methyl 2-[(3S)-[3-[2E)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates
US20090143590A1 (en) * 2004-07-19 2009-06-04 Matrix Laboratories Ltd. Process for the Preparation of Montelukast and its Salts
WO2006008562A1 (fr) * 2004-07-23 2006-01-26 Pliva-Istrazivanje I Razvoj D.O.O. Nouvelle forme de derive de benzenesulfonamide
WO2006021974A1 (fr) * 2004-08-23 2006-03-02 Morepen Laboratories Limited Procede pour synthetiser un diol (viii), intermediaire du sodium de montelukast
PL205637B1 (pl) * 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
WO2006058545A1 (fr) * 2004-11-30 2006-06-08 Medichem, S.A. Nouveau procede de preparation d'un antagoniste de leucotriene
WO2006131782A1 (fr) * 2005-06-07 2006-12-14 Glade Organics Private Limited Procede de preparation de methyl-2-(3-(2-(7-chloro-2-quinolinyl-ethenyl)-phenyl)-3-oxopropyl)benzoate
ES2358923T3 (es) 2005-07-05 2011-05-16 Teva Pharmaceutical Industries, Ltd. Purificación de montelukast.
US20070161796A1 (en) * 2005-11-16 2007-07-12 Ilan Kor-Sade Drying methods of montelukast sodium by azeotropic removal of the solvent
AR056815A1 (es) 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
US8178680B2 (en) 2005-12-13 2012-05-15 Msn Laboratories Limited Process for the preparation of Montelukast and its pharmaceutically acceptable salts
WO2007088545A2 (fr) 2006-02-02 2007-08-09 Chemagis Ltd. Nouveau procédé pour la préparation de l'acide 1-[(mercaptométhyl)cyclopropane]acétique, un intermédiaire utile dans la préparation de montelukaste et des ses sels
IL181607A0 (en) 2006-02-27 2007-07-04 Chemagis Ltd Novel process for preparing montelukast and salts thereof
US20090099367A1 (en) * 2006-03-06 2009-04-16 Farmaprojects, S. A. Process for preparing a leukotriene antagonist
CN101432267A (zh) 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
WO2007116240A1 (fr) 2006-04-12 2007-10-18 Glade Organics Private Limited Procédé amélioré pour la fabrication de montélukast sodique
US20060223999A1 (en) * 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
GB0614485D0 (en) * 2006-07-21 2006-09-27 Pliva Istrazivanje I Razvoj D Process
EP1886998A1 (fr) * 2006-08-09 2008-02-13 Esteve Quimica, S.A. Procédés de purification du montelukast et ses sels d'amine
GB0618703D0 (en) * 2006-09-22 2006-11-01 Almac Sciences Ltd Synthesis of leikotriene compounds
US7700776B2 (en) 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium
US8115004B2 (en) 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
US7271268B1 (en) 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
EP1958936A1 (fr) * 2007-02-14 2008-08-20 Inke, S.A. Procédé pour l'obtention de montelukast
EP1988079A1 (fr) * 2007-04-25 2008-11-05 Lonza Ag Processus de préparation d'alcools éthénylphényl actifs optiquement
PL205444B1 (pl) 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
EP2053043A1 (fr) 2007-10-26 2009-04-29 Inke, S.A. Sel cristallin de montelukast
DE102007061630B4 (de) 2007-12-20 2013-07-04 Formosa Laboratories, Inc. Neue Verbindungen und Herstellung von Montelukast-Natrium
CN101817818B (zh) * 2008-03-06 2011-10-26 台耀化学股份有限公司 一种用于制备孟鲁司特钠的化合物
WO2009144742A2 (fr) 2008-05-26 2009-12-03 Aptuit Laurus Pvt Limited Procédé amélioré de préparation de montélukast et de ses sels
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
KR101123292B1 (ko) * 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
WO2010064109A2 (fr) 2008-12-02 2010-06-10 Mayuka Labs Private Limited Procédé de préparation amélioré de montélukast sodique et ses intermédiaires
WO2010107404A1 (fr) 2009-03-16 2010-09-23 Mahmut Bilgic Combinaisons pharmaceutiques stables
JP2012530140A (ja) 2009-06-16 2012-11-29 メルク・シャープ・アンド・ドーム・コーポレーション グルココルチコイド受容体アゴニストとしての新規［３，２−ｃ］ヘテロアリールステロイド、組成物およびこの使用
WO2011004298A1 (fr) 2009-07-09 2011-01-13 Alembic Limited Montélukast à l'état hexaméthylène-diamine, et son utilisation pour l'élaboration de montélukast sodique
EP2287154A1 (fr) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Synthèse efficace pour la préparation de montelukast
CN101638381B (zh) 2009-09-02 2012-08-29 鲁南制药集团股份有限公司 孟鲁司特钠中间体的合成方法
WO2011042416A1 (fr) 2009-10-09 2011-04-14 Dsm Ip Assets B.V. Synthèse d'un intermédiaire optiquement actif pour la préparation de montélukast
AU2009357276A1 (en) 2009-12-23 2012-08-09 Pharmathen S.A. Improved process for the preparation of Montelukast and salts thereof
EP2552892A1 (fr) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Synthèse efficace pour la préparation de montélukast et nouvelle forme cristalline d'intermédiaires dans celle-ci
KR100990046B1 (ko) * 2010-07-30 2010-10-26 동국제약 주식회사 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
TR201009394A2 (tr) 2010-11-11 2012-06-21 Bi̇lgi̇ç Mahmut Geliştirilmiş montelukast formülasyonları.
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP2502910A1 (fr) 2011-03-15 2012-09-26 Laboratorios Lesvi, S.L. Sel de camphre sulfonique d'un intermédiaire clef du Montélukast
CN102690229B (zh) * 2011-03-23 2016-06-08 上海相辉医药科技有限公司 一种孟鲁司特钠的合成及其制备中间体
CN103842344B (zh) * 2011-07-26 2016-08-03 太阳医药高级研究有限公司 基于喹啉、喹喔啉或苯并[c]噻唑的半胱氨酰白三烯拮抗剂
WO2013077829A1 (fr) 2011-11-21 2013-05-30 Mahmut Bilgic Granulés pharmaceutiques hydrosolubles
WO2014118796A1 (fr) 2013-01-31 2014-08-07 Melody Healthcare Pvt. Ltd. Procédé in situ pour la préparation de montélukast sodique hautement pur
CN104109122B (zh) * 2013-04-16 2017-03-29 浙江奥翔药业股份有限公司 用于合成孟鲁司特的中间体化合物及其制备方法
CN104370810B (zh) * 2013-08-13 2016-10-05 天津汉瑞药业有限公司 孟鲁司特钠化合物
CN103554017B (zh) * 2013-10-25 2014-12-17 河北序能生物技术有限公司 一种孟鲁司特钠手性中间体的制备方法
CN103936671B (zh) * 2014-05-06 2015-10-28 启东东岳药业有限公司 孟鲁司特钠中间体的制备方法
CN105294556A (zh) * 2014-06-06 2016-02-03 上海迪赛诺化学制药有限公司 一种制备孟鲁司特酸的方法
CN105085391B (zh) * 2015-06-10 2017-08-22 广东默泰同创医药科技有限公司 用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用
CN105363019B (zh) * 2015-12-16 2018-04-24 新乡医学院第一附属医院 一种治疗溶血性贫血的环孢素组合物及其应用
CN108435257A (zh) * 2018-06-08 2018-08-24 福州华博立乐新材料科技有限公司 一种用于合成3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的催化剂
CN108530355B (zh) * 2018-06-08 2019-09-10 福州华博立乐新材料科技有限公司 一种3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK282986A (da) * 1985-06-18 1987-02-24 Merck Frosst Canada Inc Substitueret quinolin og farmaceutisk praeparat indeholdende en saadan forbindelse
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
JPS62258362A (ja) * 1986-05-02 1987-11-10 Terumo Corp アミド誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤
EP0271287A3 (fr) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Acides quinoléine dicarboxyliques et leurs amides
EP0318093A3 (fr) * 1987-11-25 1990-12-05 Merck Frosst Canada Inc. Acides dicarboxyliques des diaryl quinoléines et leur utilisation comme médicaments
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof
WO1990015801A1 (fr) * 1989-06-22 1990-12-27 Pfizer Inc. Sulfamides substitues et composes apparentes dans le traitement de l'asthme, de l'arthrite et des maladies apparentees

Also Published As

Publication number Publication date
CN1061407A (zh) 1992-05-27
HUT61981A (en) 1993-03-29
CA2053209C (fr) 1998-12-08
KR920008006A (ko) 1992-05-27
ES2114882T3 (es) 1998-06-16
CA2053209A1 (fr) 1992-04-13
EP0480717B1 (fr) 1998-04-15
FI914796A (fi) 1992-04-13
NL990009I1 (nl) 1999-06-01
PT99213B (pt) 1999-01-29
NL990009I2 (nl) 1999-07-01
IL99726A0 (en) 1992-08-18
HRP930751A2 (en) 1995-06-30
JP2501385B2 (ja) 1996-05-29
DE69129257T2 (de) 1998-11-05
LV12187A (lv) 1998-12-20
HU211294A9 (en) 1995-11-28
CS309591A3 (en) 1992-04-15
SK279944B6 (sk) 1999-06-11
AU8579491A (en) 1992-04-16
PT99213A (pt) 1992-09-30
HU913217D0 (en) 1992-01-28
HK1027473A1 (en) 2001-01-12
FI104897B (fi) 2000-04-28
CY2094B1 (en) 2002-04-05
YU48742B (sh) 1999-09-27
IE913609A1 (en) 1992-04-22
FI20000250A (fi) 2000-02-07
FI914796A0 (fi) 1991-10-11
AU639610B2 (en) 1993-07-29
IL99726A (en) 1998-02-22
CN1046711C (zh) 1999-11-24
MX9101551A (es) 1992-06-05
KR100227716B1 (ko) 1999-11-01
ATE165088T1 (de) 1998-05-15
SI9111647B (en) 2001-06-30
CZ281274B6 (cs) 1996-08-14
LU90284I2 (fr) 1998-11-03
DE19875039I2 (de) 2003-05-22
IL117147A (en) 2000-10-31
DE69129257D1 (de) 1998-05-20
NO914004D0 (no) 1991-10-11
IL117147A0 (en) 1996-06-18
NZ240194A (en) 1995-03-28
SI9111647A (en) 1997-12-31
HU222344B1 (hu) 2003-06-28
JPH05105665A (ja) 1993-04-27
LV12187B (en) 1999-02-20
DK0480717T3 (da) 1999-02-08
EP0480717A1 (fr) 1992-04-15
YU164791A (sh) 1994-04-05

Similar Documents

Publication Publication Date Title
HRP930751B1 (en) Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
ZA932533B (en) Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
PL309408A1 (en) Diaryl-5,6-condensed heterocyclic acids as leucotrenic antagonistic substances
EP0480708A3 (en) Hydroxyalkylquinoline ether acids as leukotriene antagonists
MY107767A (en) Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPN Proposal for the declaration of nullity of a patent
PPNO Proposal for the declaration of nullity of a patent rejected/refused
ODRP Renewal fee for the maintenance of a patent

Payment date: 20101006

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20111012